Sitagliptin Outperforms Pioglitazone on Weight and LDL in Triple Therapy

This emulated target trial gives Endocrinology and Obesity pharmacists real-world comparative data favoring sitagliptin over pioglitazone as third-line add-on therapy for metabolic parameters and stringent glycemic target attainment, though average HbA1c reduction was equivalent.

sitagliptinpioglitazoneDPP-4 inhibitorthiazolidinedionemetforminsulfonylureatype 2 diabetesHbA1cLDL cholesterolbody weightemulated target trialpropensity score matchingcomparative effectiveness Endocrinology / Diabetes / Obesity

Background Information

Sitagliptin outperforms pioglitazone in metabolic outcomes for T2DM.

This study provides insights into the comparative effectiveness of sitagliptin and pioglitazone as additions to metformin and sulfonylurea in managing type 2 diabetes mellitus (T2DM). Sitagliptin led to a higher probability of achieving intensive glycemic control (HbA1c < 6.5%) and showed greater reductions in body weight and low-density lipoprotein (LDL) cholesterol compared to pioglitazone. The findings suggest sitagliptin may offer a more favorable metabolic profile and better glycemic targets in patients with T2DM, influencing drug selection in practice. Sitagliptin may be preferred over pioglitazone for better metabolic outcomes in T2DM patients on metformin and sulfonylurea.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Kim TH, Hwang Y, Woo S, Lee K, Son Y, Park S, Kim H, Shin JY, Cho Y, Shin D, Cho D, Lee KJ, Kim CH, Rhee SY, Yon DK

Citation: Kim TH, Hwang Y, Woo S, et al. Comparative effectiveness of pioglitazone and sitagliptin added to metformin and sulfonylurea in patients with type 2 diabetes: An emulated target trial. Medicine. 2026;105(34):e50241. doi:10.1097/MD.0000000000050241

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →